Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabergoline + hydroxychloroquine
- Development stage
- Unknown
- Lead developer
- Zhebao Wu
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
cabergoline + hydroxychloroquine is an experimental combination therapy being evaluated for the treatment of cabergoline-resistant prolactinomas. Cabergoline is a potent dopamine D2 receptor agonist that serves as the standard of care for prolactin-secreting pituitary adenomas by inhibiting prolactin secretion and inducing tumor shrinkage. In cases of resistance, tumor cells often utilize autophagy as a survival mechanism to evade apoptosis. Hydroxychloroquine, a 4-aminoquinoline derivative, acts as an autophagy inhibitor by increasing lysosomal pH and preventing autophagosome-lysosome fusion. By combining these two agents, the treatment aims to sensitize resistant prolactinoma cells to the growth-inhibitory effects of cabergoline. This approach is currently being studied in clinical trials led by investigator Zhebao Wu.
- Other names
- hydroxychloroquine-Zhebao Wu-prolactinomaHCQ/CQ and CAB combined treatmenthydroxychloroquine and cabergoline
02
Targets
DRD3 (Dopamine receptor D3)DRD2 (Dopamine D2 Receptor)HTR2B (5-Hydroxytryptamine Receptor 2B)
Beyond the preview
Go deeper on cabergoline + hydroxychloroquine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabergoline + hydroxychloroquine.